沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

已收盘 08-13 16:08:14

5.130

-0.130

-2.47%

最高5.400	最低5.110	成交量106.60万
今开5.260	昨收5.260	日振幅5.51%
总市值34.63亿	流通市值34.63亿	总股本6.75亿
成交额557.40万	换手率0.16%	流通股本6.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":5.13,"timestamp":1786608494010,"preClose":5.26,"halted":0,"volume":1066000,"delay":0,"changeRate":-0.024714828897338385,"floatShares":675000000,"shares":675000000,"eps":-0.305587,"marketStatus":"已收盘","change":-0.13,"latestTime":"08-13 16:08:14","open":5.26,"high":5.4,"low":5.11,"amount":5574040,"amplitude":0.055133,"askPrice":5.205,"askSize":1000,"bidPrice":5.125,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.34006,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":5,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":5.26,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":0.6642,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996/tweets","defaultTab":"tweets","newsList":[{"id":"2659613100","title":"攻坚·产业转型丨年产能有望冲击10亿元！这家企业用“上海首张”解码南翔生命元谷“雨林式”孵化路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2659613100","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659613100?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:31","pubTimestamp":1786606260,"startTime":"0","endTime":"0","summary":"一家企业的“三级跳”在南翔生命元谷企业锐捷荣创的实验室内，工作人员正在对企业自主研发的凝胶敷料产品进行抽样检测。“产品上市后，能有效减少患者医疗费用，缩短伤口愈合期。”幸嵘透露，待骨科三类产品拿到注册证和生产许可证后，公司年产能规模有望达到5亿至10亿元。这家创新企业，正顺利从“技术验证期”迈入“规模放量期”。为此，南翔生命元谷构建起资金、服务并举的孵化培育体系。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-13/doc-ininecsr3463165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IEIH","HART","RSPH","09996","MEDX","MDEV","PTH","LNGR","GDOC","AGNG","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659867135","title":"山西省朔州市市场监管局扎实开展医疗器械质量安全交叉检查工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2659867135","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659867135?lang=zh_cn&edition=full","pubTime":"2026-08-13 13:44","pubTimestamp":1786599840,"startTime":"0","endTime":"0","summary":"检查过程中，各县区业务骨干全程跟班学习，朔州市市场监管局梳理形成观摩学习要点，现场开展业务提示指导，有效夯实基层监管人员业务基础。下一步，朔州市市场监管局将全面梳理汇总本次交叉检查发现的共性问题和薄弱环节，举一反三、查漏补缺，持续聚焦重点领域、重点品种、重点主体强化常态化监管，持续规范医疗器械经营使用秩序，严厉打击各类违法违规行为，全力保障人民群众用械安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-13/doc-inincxku3362178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1100","HART","IEIH","LGHT","159883","AGNG","BK1583","BK1574","GDOC","RSPH","MEDX","09996","PTH","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659876902","title":"股市必读：透景生命新发布《关于申报医疗器械注册获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659876902","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659876902?lang=zh_cn&edition=full","pubTime":"2026-08-13 02:27","pubTimestamp":1786559231,"startTime":"0","endTime":"0","summary":"公司公告汇总：透景生命及控股子公司脉示生物共6项医疗器械注册申请获上海市药监局受理，涉及阿尔茨海默病辅助诊断及激素、维生素检测等领域。产品包括用于阿尔茨海默病辅助诊断的β淀粉样蛋白和磷酸化Tau蛋白测定试剂盒，以及用于激素水平异常和脂溶性维生素评价的测定试剂盒。上述产品处于注册申请受理阶段，后续需经技术审评、行政审批等流程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","159883","BK1100","09996","BK1574","BK0046","BK1583","300642"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658905980","title":"透景生命（300642）披露6项医疗器械注册申请获受理，8月12日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658905980","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658905980?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:35","pubTimestamp":1786545316,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，透景生命报收于13.64元，较前一交易日上涨0.44%，最新总市值为22.13亿元。该股当日开盘13.64元，最高13.85元，最低13.5元，成交额达3842.23万元，换手率为2.04%。公告显示，上海透景生命科技股份有限公司及控股子公司上海脉示生物技术有限公司申报的6项医疗器械注册申请已获上海市药品监督管理局受理。上述产品处于注册申请受理阶段，后续需经技术审评、行政审批等流程。该事项对公司近期业绩无直接影响，最终是否获批存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","09996","BK1583","BK0046","BK0042","BK1574","BK1100","300642","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658490300","title":"乐心医疗（300562）披露血糖仪及试纸医疗器械注册证变更获受理公告，8月12日股价上涨0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658490300","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658490300?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:23","pubTimestamp":1786544590,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，乐心医疗报收于15.7元，较前一交易日上涨0.32%，最新总市值为34.32亿元。该股当日开盘15.68元，最高16.07元，最低15.5元，成交额达1.73亿元，换手率为6.56%。乐心医疗当日发布公告称，公司近日收到广东省药品监督管理局通知，申报的血糖仪和血糖试纸第二类医疗器械注册证变更事项已获受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK1574","159883","BK0251","BK1583","09996","300562","BK0109","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659376904","title":"国泰海通｜医药：国内设备招采月度数据持续回暖，关注医疗器械企业的估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659376904","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659376904?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:10","pubTimestamp":1786543800,"startTime":"0","endTime":"0","summary":"7月大型医疗设备招采边际持续回暖。设备更新政策持续落地，有望在持续水平拉动医疗设备采购。设备招采复苏不及预期，政策落地不及预期，产品价格波动风险等。报告名称：国内设备招采月度数据持续回暖，关注医疗器械企业的估值修复；报告日期：2026.08.11 报告作者：江珅（分析师），登记编号：S0880525090001赵峻峰（分析师），登记编号：S0880519080017余文心（分析师），登记编号：S0880525040111重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650540405&idx=5&sn=86c0c13590de09befa90c08ba2ab1174&chksm=897fc1f128b035fb1fdd627a07400edce4518f37b21c9c3d24fb2155693075f3b6b5e9985010&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["AGNG","BK0201","601211","BK1515","CZA","IEIH","BK0012","BK0276","BK0028","PTH","159883","BK1100","GDOC","159938","02611","LGHT","BK1147","NIFE","REVS","09996","BK1583","BK0188","BK0183","BK0184","BK1564","BK1574","MDEV","LNGR","LCO","09939","MEDX","HART","BK1161","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658091927","title":"山东省宁阳县市场监管局开展验光仪专项检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2658091927","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658091927?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:23","pubTimestamp":1786522980,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 8月11日，山东省宁阳县市场监管局执法人员对辖区眼镜经营门店开展医疗器械专项检查。本次检查聚焦电脑验光仪等验光诊疗设备，执法人员现场核对设备医疗器械注册证、定期计量检定记录，核查设备台账、使用维护记录是否完整规范，仔细查验仪器标识、出厂资料是否齐全有效。执法人员向经营商户宣讲医疗器械经营、计量器具管理相关法规，督促经营者落实主体责任，定期校验验光设备，杜绝不合格验光仪器投入使用，精准保障群众配镜验光数据准确，切实守护群众用眼健康安全。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-12/doc-inimzytn5280865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LGHT","09996","LNGR","BK1583","GDOC","BK1574","AGNG","IEIH","MDEV","PTH","RSPH","HART","MEDX","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658392180","title":"港股异动 | 沛嘉医疗-B(09996)涨超5% 上半年收入最高增长23% TaurusTrio内地植入超660例","url":"https://stock-news.laohu8.com/highlight/detail?id=2658392180","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658392180?lang=zh_cn&edition=full","pubTime":"2026-08-12 14:29","pubTimestamp":1786516164,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，沛嘉医疗-B(09996)涨超5%，截至发稿，涨4.75%，报5.29港元，成交额286.68万港元。消息面上，沛嘉医疗近日披露，今年上半年收入约为人民币4.15亿元至4.35亿元，同比增长约17.4%至23.1%。主要得益于经导管瓣膜治疗业务持续拓展，由新适应症产品成功商业化带动；神经介入业务在自研产品渗透及战略合作推动下持续增长。报告期内，TAVR植入总量约2830台，按植入量计较上年同期显著增加约36.5%，医院覆盖扩大至大中华区超850家；专为主动脉瓣反流(AR)设计的TaurusTrio®完成商业化，于中国内地植入超660例，展现出良好的临床接受度及商业化潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","09996","BK1583","BK1100","159891","KCAI","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658500149","title":"中信建投：建议关注创新医疗器械的临床、注册、放量、出海等方面的相关催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2658500149","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658500149?lang=zh_cn&edition=full","pubTime":"2026-08-11 08:07","pubTimestamp":1786406879,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LGHT","PTH","BK1574","BK0276","601066","159883","RSPH","IEIH","MEDX","BK1100","LNGR","MDEV","BK1583","09996","AGNG","GDOC","HART"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936820","title":"【百强透视】收入最高预增逾23%！沛嘉医疗-B（09996.HK）飙升超19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936820","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658936820?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:13","pubTimestamp":1786360380,"startTime":"0","endTime":"0","summary":"8月7日，港股创新器械企业沛嘉医疗-B股价迎来大幅异动飙升，截至收盘，涨幅达19.3%，报5.13港元/股。消息面，沛嘉医疗发布2026年上半年未经审核营运数据。公告显示，2026年上半年，沛嘉医疗实现收入约4.15亿元至4.35亿元，同比增长17.4%至23.1%。今年上半年，神经介入板块实现商业化规模扩大并贡献了额外的收入增长。作为创新器械企业，沛嘉医疗业务高速成长，其能否成功跻身本届港股百强榜单，值得市场持续关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-10/doc-inimvsvi8121525.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-10/doc-inimvsvi8121525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159891","BK1583","BK1574","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658981293","title":"上海：支持企业研发的创新药、现代中药和高端医疗器械全球注册认证并在当地实现销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2658981293","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658981293?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:08","pubTimestamp":1786352902,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LGHT","GDOC","PTH","159883","RSPH","159992","IBBQ","MEDX","BK1100","09996","BK1583","MDEV","LNGR","IEIH","AGNG","BK1574","HART","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135647203","title":"沛嘉医疗-B(09996)拟于8月21日审议2026年中期业绩及分红方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1135647203","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135647203?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:46","pubTimestamp":1786351570,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B(09996)8月10日公告，公司董事会将于2026年8月21日召开会议，审议并批准集团截至2026年6月30日止六个月的中期业绩及其发布事宜，并同步考虑派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658989071","title":"澳华内镜：ERCP手术机器人已进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2658989071","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658989071?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:39","pubTimestamp":1786351149,"startTime":"0","endTime":"0","summary":"证券之星消息，澳华内镜(688212)08月10日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，请问贵司的手术机器人是否为创新医疗器械？目前该手术机器人享受何种政策？这种政策是否可以和创新药的政策相比？澳华内镜回复：您好，ERCP手术机器人已进入创新医疗器械特别审查程序，在注册申报时将获得优先办理的权益，可有效缩短产品注册周期，加快产品的上市速度。详情见2026年5月8日公司对外披露的公司公告。感谢您对澳华内镜的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000020584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251","09996","BK1574","BK1583","159883","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658769609","title":"港股异动 | 沛嘉医疗-B(09996)涨超10% 上半年收入同比增长17.4%至23.1% TAVR植入量增约36.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658769609","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658769609?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:08","pubTimestamp":1786327690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，沛嘉医疗-B(09996)涨超10%，截至发稿，涨9.07%，报4.69港元，成交额439.29万港元。消息面上，沛嘉医疗公布，集团于2026年上半年收入约为人民币4.15亿元至4.35亿元，同比增长约17.4%至23.1%。收入增长主要归功于经导管瓣膜治疗业务持续拓展，由新适应症产品成功商业化带动；神经介入业务在自研产品渗透及战略合作推动下持续增长。期内TAVR植入总量约2830台，按植入量计较上年同期显著增加约36.5%，医院覆盖扩大至大中华区超850家；专为主动脉瓣反流(AR)设计的TaurusTrio®完成商业化，于中国内地植入超660例，市场接受度良好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1583","09996","BK4588","KCAI","159891","BK4585","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608374","title":"股市必读：达安基因新发布《关于下属子公司取得一个医疗器械注册证的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608374","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608374?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:32","pubTimestamp":1786300333,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，达安基因报收于5.61元，上涨0.72%，换手率1.83%，成交量25.68万手，成交额1.42亿元。公司公告汇总关于下属子公司取得一个医疗器械注册证的提示性公告广州达安基因股份有限公司下属全资子公司广州达泰生物工程技术有限公司近日取得国家药品监督管理局颁发的医疗器械注册证，产品为甲胎蛋白测定试剂盒，注册证编号：国械注准20263401671，有效期至2031年8月3日。目前该产品尚处于市场开发阶段，市场需求存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1583","09996","BK0239","BK0042","BK1100","BK0168","BK1574","BK0122","002030","BK0028","BK0159","159883","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608898","title":"股市必读：天智航新发布《关于自愿披露取得医疗器械注册证的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608898?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:10","pubTimestamp":1786299023,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，天智航报收于17.81元，上涨2.71%，换手率2.2%，成交量10.28万手，成交额1.79亿元。公司公告汇总关于自愿披露取得医疗器械注册证的公告北京天智航医疗科技股份有限公司近日获得国家药品监督管理局颁发的医疗器械注册证，产品名称为骨科手术计划软件，注册证编号国械注准20263211672，有效期至2031年8月3日，管理类别为第三类。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","159883","09996","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658675309","title":"每周股票复盘：安图生物（603658）二级子公司注销医疗器械经营资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2658675309","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658675309?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:34","pubTimestamp":1786214052,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，安图生物报收于32.43元，较上周的33.11元下跌2.05%。本周，安图生物8月3日盘中最高价报34.7元。8月7日盘中最低价报31.61元。安图生物当前最新总市值185.31亿元，在医疗器械板块市值排名13/129，在两市A股市值排名1059/5205。注销原因为业务结构优化与内部资源整合，不会对公司生产经营产生实质影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1100","603658","BK1583","09996","BK0046","159883","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117241276","title":"沛嘉医疗-B发布2026年上半年初步收入预告：预计营收约4.15亿至4.35亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1117241276","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117241276?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:58","pubTimestamp":1786111112,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B（9996.HK）于8月7日发布公告，披露了2026年上半年的初步业绩数据。根据公告显示，该公司在今年上半年预计实现营收约人民币4.15亿元至4.35亿元。相较于去年同期人民币3.534亿元的营收水平，这一数据呈现出明显的增长态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","09996","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167703149","title":"沛嘉医疗-B（09996）披露2026年上半年未经审计营运数据：收入最高达4.35亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167703149","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167703149?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:12","pubTimestamp":1786104731,"startTime":"0","endTime":"0","summary":"2026年8月7日，沛嘉医疗-B公布截至2026年6月30日止六个月的若干未经审计营运数据。公司预计，上半年实现收入约4.15–4.35亿元，较2025年同期的约3.53亿元增长17.4%–23.1%。截至2026年6月30日，公司TAVR产品组合已覆盖大中华区逾850家医院，较2025年12月31日增加约70家。公司表示，以上营运数据为初步未经审计结果，尚未经过核数师及董事会相关程序。正式中期业绩公告预计于2026年8月发布。公司提醒股东及潜在投资者在买卖公司股票时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643294","title":"沛嘉医疗-B(09996)上半年收入约为4.15亿元至4.35亿元 同比增长约17.4%至23.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643294","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657643294?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:09","pubTimestamp":1786104596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B 发布公告，该集团于2026年上半年收入约为人民币4.15亿元至4.35亿元，同比增长约17.4%至23.1%。截至2026年6月30日，集团的TAVR产品组合已将医院覆盖范围扩大至大中华区超过850家医院，较2025年12月31日增加约70间医院。于报告期内， TAVR植入总量达到约2830台，按植入量计算，较截至2025年6月30日止六个月显著增加约36.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1574","BK1100","159891","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":0.2829},{"period":"1month","weight":0.3052},{"period":"3month","weight":-0.0573},{"period":"6month","weight":-0.1516},{"period":"1year","weight":-0.3848},{"period":"ytd","weight":-0.1248}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.057115},{"month":2,"riseRate":0.5,"avgChangeRate":0.017515},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100991},{"month":4,"riseRate":0.8,"avgChangeRate":0.053778},{"month":5,"riseRate":0.6,"avgChangeRate":-0.096849},{"month":6,"riseRate":0.571429,"avgChangeRate":0.041819},{"month":7,"riseRate":0.571429,"avgChangeRate":0.044814},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.030166},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.083675}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}